Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Durvalumab And Radiation Therapy Followed by Adjuvant Durvalumab in Patients With Urothelial Cancer (T2-4 N0-2 M0) of the Bladder (DUART)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02891161
Recruitment Status : Active, not recruiting
First Posted : September 7, 2016
Last Update Posted : February 8, 2021
Sponsor:
Collaborator:
AstraZeneca
Information provided by (Responsible Party):
Monika Joshi, MD, Big Ten Cancer Research Consortium

No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : Active, not recruiting
Estimated Primary Completion Date : March 2021
Estimated Study Completion Date : March 2022